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FluorescenceThe peptide 4F is known to have potent anti-atherogenic activity. 4F is an 18 residue peptide that has a
sequence capable of forming a class A amphipathic helix. Several other class A amphipathic helical, 18 residue
peptides with the same polar face but with increasing Phe residues on the nonpolar face have been
synthesized with varying degrees of biological activity. In this work we compared the properties of the
original 2F peptide, modeled on the consensus sequence of the amphipathic helical segments of the
apolipoprotein A-I with the peptide 4F that has two Leu residues replaced with Phe. We demonstrate that the
more biologically active 4F peptide has the greatest afﬁnity for binding to several molecular species of
oxidized lipids. Lipoprotein particles can be formed by solubilizing 1-palmitoyl-2-oleoyl phosphatidylcholine
(POPC) with peptides. These solubilized lipoprotein particles extract oxidized lipid from liposomes of POPC
containing 5 mol% of oxidized lipid. The peptides with the strongest anti-atherogenic activity interact most
strongly with the oxidized lipid. The results show that there is a correlation between the biological potency of
these peptides and their ability to interact with certain speciﬁc cytotoxic lipids, suggesting that this
interaction may contribute favourably to their biological properties.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
There is increasing evidence that inﬂammation is an important
causative factor in atherosclerosis [1-9]. It has recently been suggested
that a promising approach to develop drugs against atherosclerosis is
through blocking inﬂammatory processes [10]. One of the conse-
quences of inﬂammation is the formation of lipid and protein
oxidation products. Polyunsaturated acyl chains are particularly
susceptible to oxidation, generally resulting in the sn-2 chain
becoming shorter, with less unsaturation as well as the introduction
of polar groups [11,12]. Lipid oxidation products accumulate in LDL and
are found in atherosclerotic lesions [13]. One of the most abundant
lipid oxidation products of LDL is hexadecyl azelaoyl phosphatidyl-
choline. This oxidized lipid induces apoptosis at low (micromolar)
concentrations [14]. The oxidized LDL is recognized by scavengerdylcholine; SOPC,1-stearoyl-2-
ylethanolamine; PGPC, 1-pal-
l PAF, 1-hexadecyl-2-azelaoyl-
2-(4-keto-dodec-3-ene-dioyl)
-6-octene-dioyl)phosphatidyl-
ellar vesicles
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ll rights reserved.receptors on macrophages that promote their unregulated uptake,
eventually leading to the formation of foam cells. The macrophage
scavenger receptor, CD36, has particularly high afﬁnity for phospho-
lipids with an acyl chain at the sn-2 position that incorporates a
γ-hydroxy (or oxo)-α,β unsaturated carbonyl [15,16]. The oxidized
lipids,1-palmitoyl-2-(4-keto-dodec-3-ene-dioyl)phosphatidylcholine
(KDdiA-PC) and 1-palmitoyl-2-(5-keto-6-octene-dioyl)phosphatidyl-
choline (KOdiA-PC), used in the present work, are examples of such
lipids that bind to the CD36 receptor with particularly high afﬁnity.
Oxidized phospholipids also represent ligands for another member of
the scavenger receptor class B, type I (SR-BI) [17]. The presence of
these oxidized lipids prevents binding of HDL to SR-BI and thereby
interferes with SR-BI-mediated selective uptake of cholesteryl esters
in hepatocytes. Oxidative stress plays an important role in athero-
sclerosis even in the absence of elevated levels of cholesterol [18] and
leads to the accumulation of speciﬁc oxidized phospholipids in plasma
that have both an inhibitory effect on reverse cholesterol transport as
well as promoting an accumulation of cholesterol esters in macro-
phages leading to foam cell formation and eventual deposition of
cholesterol in the form of atherosclerotic plaque. Removal of oxidized
lipids from LDL will decrease the inﬁltration of monocytes into the
artery wall thus avoiding their eventual deposition. Reducing the
levels of oxidized lipids in LDL has been proposed as a potential target
to prevent cardiovascular disease [19,20].
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sn-2 position of oxidized phospholipids reorients itself so that it
protrudes from the membrane bilayer. This has been referred to as the
“lipid whisker model” [21]. Molecular dynamic simulations provide
support for this conformation of oxidized lipids [22]. This leaves only
one acyl chain of the oxidized lipids buried in the membrane. The
presence of these oxidized acyl chains in the sn-2 position plays an
important role in their biological activity [23]. This is likely a
consequence of their conﬁguration that would be expected to allow
facile extraction of oxidized lipids from the membrane. In support of
this is the ﬁnding that ﬂuorescently labelled forms of these oxidized
lipids are readily transferred from aqueous phospholipid dispersions
or preloaded LDL to vascular smooth muscle [24].
The protective effect of HDL against atherosclerosis is not only
dependent on a higher concentration of HDL in the blood but is also
dependent on the molecular composition of the HDL [25]. Small
variations in apo A-I can have major consequences in its ability to
protect against atherosclerosis. For example, chlorination of apo A-I
by myeloperoxidase reduces its effectiveness in stimulating choles-
terol efﬂux [26]. A natural mutant form of human apo A-I, apo
A-IMilano, has been recently considered for therapy in atherosclerosis
[27–36]. One way in which the properties of HDL can be modiﬁed is
by the binding of peptides. It is known that bound peptides represent
about 1% of the protein mass of HDL [37]. In addition, we ﬁnd that an
anti-atherogenic amphipathic helical peptide 3F-2, analogous to 4F,
binds to the HDL fraction in vivo to a much greater extent than does aFig. 1. Structure of the oxidized forms of phosphatidylcholine used in this work.
Fig. 2. DSC curves of DEPE with increasing mol fractions of KOdiA-PC. Top four scans are
heating scans, bottom four are cooling scans. DSC scans of DEPE alone (0) and in the
presence of increasing mole fractions of KOdiA-PC. Lipid concentration 5 mg/mL in
20 mM PIPES, 1 mM EDTA, 150 mMNaCl with 0.002% NaN3, pH 7.40. Scan rate 2° C/min.
Curves have been displaced along the y-axis for presentation. Excess heat capacity is
expressed per mole of DEPE.
Fig. 3. Shift of the gel to liquid crystalline phase transition temperature (top curves) and
the bilayer to hexagonal phase transition temperature (bottom curves) with mole
fraction of KOdiA-PC. Numbers near each line correspond to the slope of the regression
line. The positive linear regression for the dependence of TH provides a measure of the
promotion of positive curvature by the KOdiA-PC.
Fig. 4. Changes in the ﬂuorescence emission spectrum of 4F (7.3 μM in the cuvette) with
successive additions of oxidized lipid in solution at 25 °C.
Fig. 5. Shift in the Trp emission wavelength upon addition of Azelaoyl PC or PGPC (top curve
with 2F (right).
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biological function [38]. It is clear now that simple modiﬁcations in
the sequence of 4F, such as changing Phe-3 or Phe-14 to Leu changes
the in vivo properties and HDL binding capacity of the original
peptide dramatically [38]. Recently biotinyl-4F was studied and it was
concluded that 4F does not associate with HDL. It is possible that the
authors followed the biotinyl label and not intact 4F, which may have
degraded. Thus the biotin-containing fragments may have appeared
away from HDL. Since the self-association and lipid or lipoprotein
associating properties depend on the end protecting groups, this may
account for the differing results obtained by Getz et al. [39] with the
biotinyl-4F peptide.
Some peptide mimetics of apo A-I are effective in inhibiting
atherosclerosis in atherosclerosis-sensitive animal models [40–47] as
well as other inﬂammatory disorders [48–51]. They have been shown
in vitro to inhibit oxidized phospholipids-induced monocyte chemo-
taxis and to scavenger oxidized lipids from LDL. We have earlier
shown that the lipid binding ability does not determine the biological
activity of these peptide analogs. For example, using the same amino
acids in different arrangements of the nonpolar face of the class A
amphipathic helix, despite their ability to associate with normal lipids
with high afﬁnity, possesses different biological activities. This is
correlated to their ability to inhibit LDL-induced monocyte chemo-
taxis. Among these peptides, peptide 4F was an ideal candidate to
study in detail. The peptide 4F is active in inhibiting lipopolysacchar-
ide-induced inﬂammatory responses [52]. The enantiomer of 4F, the
most effective peptide, D-4F, is orally active in vivo and was shown to
reduce inﬂammatory responses to inﬂuenza virus in mice [40] and to
synergize with statin to cause regression of lesions [53]. This peptide
also improves vascular reactivity in a rat model of diabetes [54]. D-4F
has also been shown to protect against the production of oxidized
cholesterol [55].s) and the binding isotherms for the interaction of Azelaoyl PC or PGPC with 4F (left) or
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synergizing with statin to even regress already existing athero-
sclerotic lesions in apo E-null mice [53] were shown (by surface
plasmon resonance) to bind to oxidized lipids more avidly by several
folds than either apo A-I or a less active analogous peptide, 3F14 [56].
We have extended this observation by measuring the binding of
several different forms of oxidized phosphatidylcholine in solution
without the use of solid supports. We demonstrate the ability of
these peptides to interact with oxidized lipids present in a bilayer, in
addition to oxidized lipid that is free in solution. We have also
compared the afﬁnity of the peptide 4F with that of 2F that was not
used in the previous study. Thus this study demonstrates dramatic
differences in the properties of two peptides with respect to their
anti-inﬂammatory properties as a consequence of just replacing two
central Leu residues with Phe. The difference between Leu and Phe,
especially in the context of membrane binding proteins and their
properties is not well appreciated despite one being an aromatic side
chain and the other an aliphatic side chain, capable of stronger
interdigitation with the lipid acyl chains, as pointed out by us in
previous papers [38,57]. The properties of lipid complexes with 2F
and 4F have recently been compared using NMR methods [58]. One
of the mechanisms by which apo A-I and the anti-atherogenic
peptides can protect against atherosclerosis is by removal of oxidized
lipid components from LDL [59,60]. While co-incubation of apo A-I
with LDL did not inhibit LDL-induced monocyte chemotaxis, co-
incubation with peptide 4F was highly effective and 2F had moderate
activity. These results correlate well with their ability to inhibit
atherosclerosis in mouse models of atherosclerosis. Therefore, we
have tested peptides 2F and 4F for their ability to interact with
speciﬁc oxidized phospholipids in bilayers using various methodsFig. 6. Shift in the Trp emissionwavelength upon addition of KDdiA-PC or KOdiA-PC (top curv
or with 2F (right).and the relationship between the strength of this interaction and the
biological properties of these molecules.
2. Experimental methods
2.1. Materials
Peptideswere synthesized by the solid phasemethodwith a Protein
Technologies PS-3 automatic peptide synthesizer using the procedures
described previously [45,61]. Peptides were puriﬁed using a prepara-
tive HPLC system (Beckman Gold) and the purity of the peptides was
ascertained by mass spectral analysis and analytical HPLC. The
sequence of 2F is Ac-DWLKAFYDKVAEKLKEAF-NH2 and of 4F is Ac-
DWFKAFYDKVAEKFKEAF-NH2. The phospholipids 1-palmitoyl-2-
oleoyl phosphatidylcholine (POPC), 1-stearoyl-2-oleoyl phosphatidyl-
choline (SOPC) and di-dielaidoyl phophatidylethanolamine (DEPE) as
well as the oxidized lipids 1-palmitoyl-2-glutaryl-sn-glycero-3-phos-
phocholine (PGPC) and 1-hexadecyl-2-azelaoyl-sn-glycero-3-phos-
phocholine (Azelaoyl PAF) were obtained from Avanti Polar Lipids
(Alabaster, AL). The oxidized lipids, 1-palmitoyl-2-(4-keto-dodec-3-
ene-dioyl) phosphatidylcholine (KDdiA-PC) and 1-palmitoyl-2-(5-
keto-6-octene-dioyl) phosphatidylcholine (KOdiA-PC)were purchased
from Cayman Chemical (Ann Arbor, MI). The structures of the oxidized
lipids are shown in Fig. 1.
2.2. Differential scanning calorimetry
Measurements were made using a Nano II Differential Scanning
Calorimeter (Calorimetry Sciences Corporation, Lindon, UT). The scan
rate was 2 °C/minwith a delay of 5 min between sequential scans in aes) and the binding isotherms for the interaction of KDdiA-PC or KOdiA-PCwith 4F (left)
Table 1
Equilibrium binding constants for the binding of oxidized lipids with the peptides 2F
and 4F.
Lipid 4F 2F
K (M−1) ΔG (kcal/mol) K (M−1) ΔG (kcal/mol)
PGPC 1.6×107 −9.9 3.1×106 −8.9
Azelaoyl PAF 1.4×107 −9.8 2.7×106 −8.6
KOdiA-PC 1.4×107 −9.8 9.9×106 −9.6
KDdiA-PC 1×108 −11 1.4×107 −9.8
1971R.F. Epand et al. / Biochimica et Biophysica Acta 1788 (2009) 1967–1975series to allow for thermal equilibration. The features of the design of
this instrument have been described [62]. DSC curves were analyzed
by using the ﬁtting program, DA-2, provided by Microcal Inc.
(Northampton, MA) and plotted with Origin, version 5.0. Dry lipid
ﬁlms of DEPE, SOPC or SOPC+10 mol% KOdiA-PC were suspended in
20 mM PIPES, 1 mM EDTA, 150 mM NaCl with 0.002% NaN3, pH 7.40
with or without addition of the peptide 4F by vortexing above the
phase transition temperature of the lipid to form multilamellar
vesicles (MLVs). The concentration of MLV in the samples studied was
maintained at 5 mg/mL for the DEPE samples and 2.5 mg/mL for the
SOPC samples. The cell volume is 340 μL.
2.3. Binding isotherm for the interaction of 4F or 2F with oxidized lipid
The change in Trp ﬂuorescence from the peptide was used to
establish a binding curve for the interaction of eachof the oxidized lipids
with peptide. A solution of 7.5 μM peptide was placed in the
ﬂuorescence cuvette with stirring and small aliquots of a solution of
oxidized lipids in ethanol solutionwerediluted into buffer to thedesired
concentration. The reaction was carried out in 10 mM HEPES buffer,Fig. 7. Interaction between POPC liposomes containing 5% oxidized lipids and lipopeptide par
shows titration with LUVs containing KDdiA-PC or top, right panel LUVs containing KOdiA-
lipopeptide titrated with LUVs containing KDdiA-PC (■) or KOdiA-PC (▾) lower right hand0.14 M NaCl, 1 mM EDTA, pH 7.4 at 25 °C. Tryptophan ﬂuorescence was
monitored by recording the spectrum between 310 and 370 nm after
each addition of oxidized lipid. The excitation wavelength was 295 nm
with excitation and emission slits set at 8 and 4 nm bandpass,
respectively. Scattered light intensity was reduced by the use of
polarizing ﬁlters, setting the excitation ﬁlter at 90° and the emission
ﬁlter at 0°. Appropriate correction factorswere applied and the intensity
at the emissionmaximum of the peptide alonewas subtracted from the
values of samples with lipid in order to construct a binding isotherm.
The binding afﬁnity was calculated as a partition binding constant,
using the equation:
K = Pb½ = L½   Pf½ = W½  ð1Þ
where Pb and Pf are the concentrations of peptide bound and peptide
free, respectively. L and W are the concentrations of lipid and water,
respectively.
2.4. Preparation of large unilamellar vesicles (LUV)
Lipids were codissolved in chloroform/methanol (2/1, v/v). The
solvent was then evaporated under a stream of nitrogenwith constant
rotation of a test tube so as to deposit a uniform ﬁlm of lipid over the
bottom third of the tube. Last traces of solvent were removed by
placing the tube under high vacuum for 3 h. The lipid ﬁlm was then
hydrated with buffer, as indicated for speciﬁc experiments. LUVs were
made from this suspension by 5 freeze-thaw cycles and extruded 10
times through two polycarbonate ﬁlters with 100 nm pore size, in a
Lipex barrel extruder under nitrogen pressure (Lipex Biomembranes
Inc.). Vesicles were kept on ice under Argon gas and used within a fewticles composed of POPC and either 2F or 4F at a lipid to peptide ratio of 3. Top, left panel
PC, into a solution of lipopeptide of 2F (▴) or 4F (■). Lower, left panel titration of 4F
panel of 2F lipopeptide, titrated with LUVs containing KDdiA-PC (■) or KOdiA-PC (▴).
Fig. 8. DSC of SOPC (1 and 1′) or SOPC+10 mol% KOdiA-PC (2 and 2′) alone or with the
addition of 4F to SOPC (3 and 3′) or to SOPC+10mol% KOdiA-PC (4 and 4′). The lipid to
peptide molar ratio is 500. Upper half of the ﬁgure: heating curves, while the lower half
(curves with ′) are cooling curves. Each specimen was heated and cooled three times.
Lipid concentration is 2.5 mg/mL in 20 mM PIPES, 1 mM EDTA, 150 mM NaCl with
0.002% NaN3, pH 7.40. Scan rate 1 °C/min. Curves have been displaced along the y-axis
for presentation. Excess heat capacity is expressed per mole of SOPC.
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phosphate assay of Ames [63].
2.5. Interaction between discoidal lipopeptides and liposomes with
oxidized lipids
The peptides 4F and 2F were used to solubilize POPC in the form of
lipoprotein particles. 5 μM peptide was incubated for 1 h at room
temperature with MLVs of POPC at a lipid to peptide molar ratio of 3.
The time course of the solubilization was followed by right angle light
scattering in an SLM Aminco, Model II spectroﬂuorometer, setting
both excitation and emission monochrometers at 400 nm. The
clariﬁcation of the turbidity was complete within 1–2 h of incubation.
These lipoprotein particles were then titrated with LUVs of POPC and
the Trp ﬂuorescence of the peptide was monitored over time. No
change of ﬂuorescence was observed, suggesting that the lipoprotein
particles were saturated with phospholipid.
These lipoprotein particles were then titrated at 25 °C with
successive additions of small aliquots of solutions of LUVs composed
of either POPC:KDdiA-PC (95:5) or POPC:KOdiA-PC (95:5). The
decrease in the ﬂuorescence from Trp of the peptide was monitored
as a function of time.
2.6. Isothermal Titration Calorimetry (ITC)
A 32 μM solution of 4F or 2F was made in 20 mM PIPES buffer, pH
7.4, containing 0.14 M NaCl and 1 mM EDTA and used to ﬁll the
calorimeter cell (1.4276 mL) which was equilibrated to 30 °C in a
MicroCal VP-ITC instrument (MicroCal Inc, Southampton, MA).
Solutions of 1-palmitoyl-lysophosphatidylcholine (LPC) were made
at a concentration of 860 μM in matching buffer and placed in the
syringe. A volume of 20 μL of LPC was titrated into the solution of
peptide with a constant stirring at 300 rpm. Data was analyzed and
plotted using the program Origin 5.0 and ﬁtted with programs for two
sites binding models provided by the manufacturer.
3. Results
3.1. Oxidized phospholipids promote positive membrane curvature
Using DSC we show that the oxidized lipids raise the bilayer to
hexagonal phase transition temperature of DEPE, indicating that they
promote positive curvature and stabilize bilayer properties. As an
example we show a family of heating and cooling DSC curves of DEPE
with the addition of several different mole fractions of KOdiA-PC
(Fig. 2). The shift of the bilayer to hexagonal transition temperature is
proportional to the amount of KOdiA-PC added (Fig. 3), with the value
for the heating curves being 378±38, which is comparatively high.
Similar values were obtained introducing other oxidized lipids into
DEPE.
3.2. Binding isotherm for the interaction of 4F or 2F with oxidized lipid
We initially studied the binding of these peptides with oxidized
lipids by adding them directly to a solution of the peptide, in the
absence of any phospholipid or liposomes. Titrating the peptides with
the oxidized lipids Azelaoyl PAF or with PGPC there was a progressive
increase in the intensity of Trp emission from the peptide shown for
PGPC (Fig. 4, top graph). In contrast, the two oxidized lipids with α,β
unsaturated ketones, KOdiA-PC and KDdiA-PC, caused a quenching of
the peptides Trp ﬂuorescence (Fig. 4, bottom). This quenching was not
a result of an inner ﬁlter effect because of the low absorbance of the
mixtures at the excitation wavelength of 295 nm nor was it the result
of light scattering, as veriﬁed by the wavelength dependence of the
absorbance. In general when lipids bind to peptides with a Trp residue
one would expect that the ﬂuorescence emission intensity wouldincrease. However, highly polarizable groups are known to be good
quenching agents. This is likely the reason why the oxidized lipids
with α,β unsaturated ketones induce quenching of the Trp of these
peptides, while the lipids with simple unconjugated carboxylic acids
do not have this effect. With Azelaoyl PAF and PGPC, the emission
wavelength of the Trp decreased from about 340 nm to about 333 nm,
conﬁrming the binding of the oxidized lipids to both 2F and 4F (see
Fig. 5, top curves). This is also the case for KOdiA-PC and KDdiA-PC
(Fig. 6, top curves). The binding isotherms are shown in the bottom
curves of Figs. 5 and 6 and the values for the equilibrium binding
constant and free energy of binding are given in Table 1.
3.3. Interaction between discoidal lipopeptides and liposomes with
oxidized lipids
Lipoprotein particles of POPC and 2F or 4F were titrated with
successive additions of small aliquots of LUV made from POPC and
containing 5 mol% of either KOdiA-PC or KDdiA-PC. This resulted in a
quenching of the Trp ﬂuorescence of the peptide in the lipoprotein
particle. There was no quenching of the Trp ﬂuorescence of these
peptides when the lipoprotein particles were titrated with POPC not
containing oxidized lipid. Hence the inclusion of only 5 mol% oxidized
lipid into the membrane resulted in the peptides binding to the
liposomes with high afﬁnity. This demonstrates the ability of these
peptides to interact with oxidized lipids already contained in a
membrane bilayer. The peptide 4F is more potent than 2F (Fig. 7, top
panels). Of the two oxidized lipids, the KDdiA-PC, having the longer
sn-2 chain, are more potent to interact with the peptides (Fig. 7,
bottom panels), particularly for 4F (Fig. 7, bottom, left panel).
Table 2
Thermodynamics of binding of LPC to 4F or 2F data from ITC ﬁtted with an equation for
two independent binding sites.
Peptide K1 (M−1) ΔH1 (kcal/mol) ΔS1 K2 (M−1) ΔH2 (kcal/mol) ΔS2
4F 1.8×106 −2.8 19.3 5×104 −1.5 16.6
2F 1.6×106 −4.0 15.3 8.6×104 −1.6 17.3
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LUVs sedimenting, however, the total amount of each peptide remained
in the supernatant. This demonstrates that the loss of Trp ﬂuorescence
was not caused by the peptide binding to the oxidized lipid in the LUVs,
but rather that the oxidized lipids were being extracted into the
lipopeptide particle that remained in the supernatant.
Evidence that the interaction of the oxidized lipid with the peptide
results in the extraction of the oxidized lipid from the membrane
comes fromDSC studies (Fig. 8). SOPCwas chosen for this because this
lipid has the structure of phospholipids common to biological
membranes with a saturated acyl chain at sn-1 and an unsaturated
chain at sn-2. SOPC is also a lipid with a low gel to liquid crystalline
phase transition at 4.9 °C. Addition of KOdiA-PC lowers the transition
temperature to 3.1 °C, while addition of 4F has a negligible effect on
the phase transition temperature. However, addition of the same
amount of 4F to themixture of SOPC+KOdiA-PC signiﬁcantly reverses
the lowering of the phase transition temperature caused by the
oxidized lipid (Fig. 8). This is consistent with the 4F extracting KOdiA-
PC from the membrane and reversing its effect in lowering the phase
transition temperature of SOPC.
3.4. Isothermal Titration Calorimetry (ITC)
Because these oxidized lipids have shorter sn-2 acyl chains and
they also promote positive membrane curvature (Fig. 2), these lipids
have some relationship in terms of chemical structure and effects on
membrane properties to lysophosphatidylcholine (LPC). Although
there are differences between the structures of LPC and of oxidized
lipids, the comparison allows one to determine if the observed
interactions have some degree of speciﬁcity. Because LPC is more
readily available than the speciﬁc forms of oxidized lipids, we used LPC
to titrate 4F and 2F using both ITC and ﬂuorescence titration. TheseFig. 9. ITC data obtained by injection of successive aliquots of LPC into 32 μM 4F (left) or 32 μ
curves are the calculated enthalpy.measurements serve to compare the binding of an amphiphile, LPC,
that does not have an sn-2 acyl chain that can protrude from the
membrane surface with the binding of oxidized lipids to these
peptides. In addition, ITC provides an independent determination of
binding afﬁnity that can be compared with that obtained from
ﬂuorescent titration, as a test of the validity of the latter method. The
ITC data are presented (Fig. 9). The curves were ﬁtted to two binding
constants of different afﬁnities and the values for the enthalpy and
entropy of the reaction are summarized (Table 2). The results show
that there is no signiﬁcant difference in the binding afﬁnity of 4F vs. 2F
to LPC, unlike the case of the oxidized lipids inwhich 4F binds about 5-
fold more strongly (Table 1).
We also measured the binding of LPC to these peptides by
monitoring the Trp ﬂuorescence of the peptides. This titration could
be ﬁtted with a single binding isotherm with values of 6.8×105 M−1
and 9.4×105 M−1 for the partition binding constants of 4F and 2F,
respectively. These values are close to, but somewhat lower than the
high afﬁnity binding constant obtained by ITC. In addition, both
methods indicate that 2F and 4F have similar binding afﬁnities for LPC.
The more complex binding proﬁle found with ITC, requiring two
binding constants to ﬁt the data, may be the result of interactions
between LPC and peptide that have enthalpic contributions but do not
cause change in the Trp ﬂuorescence of the peptide.M 2F (right). Upper curves are the experimentally observed heat changes and the lower
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Although peptides such as 4F have been designed from a
consensus sequence of the amphipathic helical segments of the
apolipoprotein A-I, this peptide is not just a simple apo A-I mimetic,
since it exhibits protective effects against cardiovascular disease at
much lower concentrations than that of apo A-I. This is also shown by
the fact that orders of magnitude more apo A-IMilano are required to
attain a cardio-protective effect, compared with the peptide 4F. In the
present study we compare 4F with 2F, a similar 18 residue
amphipathic helical peptide that has low cardiovascular protective
potency even though it differs from 4F only in the substitution of two
Leu residues of 2Fwith Phe in 4F. Peptide 2F has also been shown to be
less effective than 4F in vitro in inhibiting LDL-induced monocyte
chemotaxis in a co-culture system [64]. Thus we investigated the
abilities of these two peptides to bind to the different oxidized lipids
shown in Fig. 1.
We ﬁnd that oxidized lipids raise the bilayer to hexagonal phase
transition temperature. This is the same effect on membrane
curvature as we had found with the amphipathic helical peptides
[65]. The amphipathic helical peptides used in this work are known to
bind more strongly to smaller vesicles having higher positive
curvature on the exterior. This could be a factor promoting the
attraction of the peptides to regions of the membrane containing
oxidized lipids and hence higher local positive curvature. Earlier we
had suggested that 4F because of clustering of pi-electrons at the
center of the nonpolar face, would possess high afﬁnity to oxidized
lipids [66]. Indeed, this was supported by a recent study using surface
plasmon resonance, which demonstrated higher afﬁnity of 4F for
several forms of oxidized lipids, compared with apo A-I. In the present
study we have analyzed the binding of 4F and 2F in solution with
several forms of oxidized lipids as well as demonstrating the
interaction of these peptides in the form of lipoprotein particles
with bilayer liposomes containing oxidized lipids. This latter arrange-
ment mimics the situation in vivo since 4F has been shown to
associate with small preβ-HDL-like particles that would resemble
those we have made for this in vitro study [64]. These lipoprotein
particles could then extract oxidized lipids from other lipid structures,
such as oxidized LDL. Evidence from the reversal of the effect of
KOdiA-PC by 4F (Fig. 8), supports this mechanism.
The binding afﬁnity of PGPC and of KOdiA-PC for 4F (Table 1) is 9
and 4.5 fold lower than that previously found using surface plasmon
resonance [56]. The difference may reﬂect a stabilization of the lipid–
peptide complex by the solid support required for surface plasmon
resonance. Our results demonstrate that 4F binds to oxidized lipids
with almost 10-fold higher afﬁnity than 2F, except for KOdiA-PC,
where the difference in binding afﬁnity to the two peptides is smaller
(Table 1). We cannot explainwhy KOdiA-PC is the only form to show a
smaller difference in binding afﬁnity to the two peptides. The oxidized
lipid with the highest afﬁnity for binding these peptides is KDdiA-PC.
Interestingly, it binds more avidly than the structurally similar KOdiA-
PC, particularly to 4F. The difference between these two forms of
oxidized phosphatidylcholine is the length of the acyl chain at the
sn-2 position, with KDdiA-PC having a 12 carbon chain at this
position, at least 4 carbons longer than any of the other forms of
oxidized lipid. This observation would ﬁt well the whisker hypothesis
that demonstrates a reorientation of the sn-2 acyl chain to extend out
of the membrane [21]. We envisage that if the sn-2 oxidized acyl chain
were able to extend out of the membrane, then the longer it is, the
greater the length of the segment of the lipid that would be accessible
for interactionswith the amphipathic helical peptides. This hypothesis
is supported by the ﬁndings that LPC that does not have an sn-2 chain,
binds to the peptides with one or two orders of magnitude lower
afﬁnity. In addition, the binding afﬁnity of 2F and 4F to LPC is similar,
unlike the situation with the oxidized lipids in which 4F binds with a
10-fold higher afﬁnity. The correlation between the protective effect ofthe peptide and the afﬁnity of binding to oxidized lipids also agrees
with the ﬁndings using surface plasmon resonance [56].
Just as the apolipoprotein A-I affects several functions in
contributing a protective cardiovascular effect, so too would these
anti-atherosclerotic peptides be expected to have more than one site
of action. However, many of the important effects of these peptides
can be correlated with removal of oxidized lipids resulting in lowering
the inﬂammatory response and also lowering the arterial deposition
of cholesterol. These peptides are a component of the pre-β HDL
fraction of circulating lipoprotein particles. The demonstration in this
work that small lipoprotein particles containing 4F are able to interact
with oxidized lipid components in a different membrane provides a
molecular basis by which these peptides can neutralize the effects of
oxidized lipids.
Acknowledgements
This work was funded by grant NA 6178 from the Heart and Stroke
Foundation of Ontario (to RME) and by a PPG grant NIHHL 34343 from
NIH (to GMA).References
[1] R. Ross, Atherosclerosis—an inﬂammatory disease, N. Engl. J. Med. 340 (1999)
115–126.
[2] M. Madjid, I. Awan, J.T. Willerson, S.W. Casscells, Leukocyte count and coronary
heart disease: implications for risk assessment, J Am. Coll. Cardiol. 44 (2004)
1945–1956.
[3] D.O. Haskard, Accelerated atherosclerosis in inﬂammatory rheumatic diseases,
Scand. J. Rheumatol. 33 (2004) 281–292.
[4] R. Stocker, J.F. Keaney, Role of oxidative modiﬁcations in atherosclerosis, Physiol.
Rev. 84 (2004) 1381–1478.
[5] R. Paoletti, A.M. Gotto Jr., D.P. Hajjar, Inﬂammation in atherosclerosis and
implications for therapy, Circulation 109 (2004) III20–III26.
[6] J.T. Willerson, P.M. Ridker, Inﬂammation as a cardiovascular risk factor, Circulation
109 (2004) II2–10.
[7] I. Jialal, S. Devaraj, S.K. Venugopal, C-reactive protein: risk marker or mediator in
atherothrombosis? Hypertension 44 (2004) 6–11.
[8] M.F. Linton, S. Fazio, Cyclooxygenase-2 and inﬂammation in atherosclerosis, Curr.
Opin. Pharmacol. 4 (2004) 116–123.
[9] L.E. Spieker, F. Ruschitzka, T.F. Luscher, G. Noll, HDL and inﬂammation in
atherosclerosis, Curr. DrugTargets. Immune.Endocr.Metabol. Disord.4 (2004)51–57.
[10] C.Q. Meng, Inﬂammation in atherosclerosis: new opportunities for drug discovery,
Mini. Rev. Med. Chem. 5 (2005) 33–40.
[11] M.R. Domingues, A. Reis, P. Domingues, Mass spectrometry analysis of oxidized
phospholipids, Chem. Phys. Lipids 156 (2008) 1–12.
[12] V.A. Tyurin, Y.Y. Tyurina, W. Feng, A. Mnuskin, J. Jiang, M. Tang, X. Zhang, Q. Zhao,
P.M. Kochanek, R.S. Clark, H. Bayir, V.E. Kagan, Mass-spectrometric characteriza-
tion of phospholipids and their primary peroxidation products in rat cortical
neurons during staurosporine-induced apoptosis, J. Neurochem. 107 (2008)
1614–1633.
[13] J.A. Berliner, N.M. Gharavi, Endothelial cell regulation by phospholipid oxidation
products, Free Radic. Biol Med. 45 (2008) 119–123.
[14] R. Chen, L. Yang, T.M. McIntyre, Cytotoxic phospholipid oxidation products. Cell
death frommitochondrial damage and the intrinsic caspase cascade, J. Biol. Chem.
282 (2007) 24842–24850.
[15] E.A. Podrez, E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P.J. Finton, L. Shan, B.
Gugiu, P.L. Fox, H.F. Hoff, R.G. Salomon, S.L. Hazen, Identiﬁcation of a novel family
of oxidized phospholipids that serve as ligands for the macrophage scavenger
receptor CD36, J. Biol. Chem. 277 (2002) 38503–38516.
[16] S.L. Hazen, Oxidized phospholipids as endogenous pattern recognition ligands in
innate immunity, J. Biol. Chem. 283 (2008) 15527–15531.
[17] M.Z. Ashraf, N.S. Kar, X. Chen, J. Choi, R.G. Salomon, M. Febbraio, E.A. Podrez,
Speciﬁc oxidized phospholipids inhibit scavenger receptor BI-mediated selective
uptake of cholesteryl esters, J. Biol. Chem. 283 (2008) 10408–10414.
[18] C. Bernal-Mizrachi, A.C. Gates, S. Weng, T. Imamura, R.H. Knutsen, P. DeSantis, T.
Coleman, R.R. Townsend, L.J. Muglia, C.F. Semenkovich, Vascular respiratory
uncoupling increases blood pressure and atherosclerosis, Nature 435 (2005)
502–506.
[19] N.A. Le, Reducing oxidized lipids to prevent cardiovascular disease, Curr. Treat.
Options Cardiovasc. Med. 10 (2008) 263–272.
[20] D.J. Rader, A. Daugherty, Translating molecular discoveries into new therapies for
atherosclerosis, Nature 451 (2008) 904–913.
[21] M.E. Greenberg, X.M. Li, B.G. Gugiu, X. Gu, J. Qin, R.G. Salomon, S.L. Hazen, The lipid
whisker model of the structure of oxidized cell membranes, J. Biol. Chem. 283
(2008) 2385–2396.
[22] H. Khandelia, O.G. Mouritsen, Lipid gymnastics: evidence of complete acyl chain
reversal in oxidized phospholipids from molecular simulations, Biophys. J. 96
(2009) 2734–2743.
1975R.F. Epand et al. / Biochimica et Biophysica Acta 1788 (2009) 1967–1975[23] G. Subbanagounder, N. Leitinger, D.C. Schwenke, J.W. Wong, H. Lee, C. Rizza, A.D.
Watson, K.F. Faull, A.M. Fogelman, J.A. Berliner, Determinants of bioactivity of
oxidized phospholipids. Speciﬁc oxidized fatty acyl groups at the sn-2 position,
Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2248–2254.
[24] A. Moumtzi, M. Trenker, K. Flicker, E. Zenzmaier, R. Saf, A. Hermetter, Import and
fate of ﬂuorescent analogs of oxidized phospholipids in vascular smooth muscle
cells, J. Lipid Res. 48 (2007) 565–582.
[25] M. Navab, G.M. Ananthramaiah, S.T. Reddy, B.J. Van Lenten, B. Ansell, G.C. Fonarow,
K. Vahabzadeh, S. Hama, G. Hough, N. Kamranpour, J.A. Berliner, A. Lusis, A.M.
Fogelman, The oxidation hypothesis of atherogenesis: the role of oxidized
phospholipids and HDL, J. Lipid Res. 45 (2004) 993–1007.
[26] S.J. Nicholls, L. Zheng, S.L. Hazen, Formation of dysfunctional high-density
lipoprotein by myeloperoxidase, Trends Cardiovasc. Med. 15 (2005) 212–219.
[27] P.W. Wilson, Recombinant apolipoprotein A-I Milano effects on coronary
atherosclerosis, Curr. Cardiol. Rep. 6 (2004) 438.
[28] H.B. Brewer, Focus on high-density lipoproteins in reducing cardiovascular risk,
Am. Heart J. 148 (2004) S14–S18.
[29] C.R. Sirtori, ApoA-1 Milano and regression of atherosclerosis, JAMA 291 (2004)
1319.
[30] H. Kim, E.L. Jacobson, M.K. Jacobson, A.G. Lacko, ApoA-1 Milano and regression of
atherosclerosis, JAMA 291 (2004) 1319.
[31] M.H. Davidson, Biologic therapies for dyslipidemia, Curr. Atheroscler. Rep. 6
(2004) 69–72.
[32] D. Duffy, D.J. Rader, Drugs in development: targeting high-density lipoprotein
metabolism and reverse cholesterol transport, Curr. Opin. Cardiol. 20 (2005)
301–306.
[33] L.G. Futterman, L. Lemberg, Apo a-I Milano, Am. J. Crit. Care 14 (2005) 244–247.
[34] S. Kaul, B. Coin, A. Hedayiti, J. Yano, B. Cercek, K.Y. Chyu, P.K. Shah, Rapid reversal of
endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by
recombinant apolipoprotein A-I(Milano)-phospholipid complex, J. Am. Coll.
Cardiol. 44 (2004) 1311–1319.
[35] D. Kazi, J.A. Farmer, Raising high-density lipoprotein cholesterol: innovative
strategies against an old adversary, Curr. Atheroscler. Rep. 7 (2005) 88–94.
[36] X. Zhu, G. Wu, W. Zeng, H. Xue, B. Chen, Cysteine mutants of human
apolipoprotein A-I: a study of secondary structural and functional properties,
J. Lipid. Res. 46 (2005) 1303–1311.
[37] G.L. Hortin, R.F. Shen, B.M. Martin, A.T. Remaley, Diverse range of small peptides
associated with high-density lipoprotein, Biochem. Biophys. Res. Commun. 340
(2006) 909–915.
[38] S.P. Handattu, D.W. Garber, D.C. Horn, D.W. Hughes, B. Berno, A.D. Bain, K. Mishra,
M.N. Palgunachari, G. Datta, G.M. Anantharamaiah, R.M. Epand, ApoA-I mimetic
peptides with differing ability to inhibit atherosclerosis also exhibit differences in
their interactions with membrane bilayers, J. Biol. Chem. 282 (2007) 1980–1988.
[39] G.D. Wool, T. Vaisar, C.A. Reardon, G.S. Getz, An apoA-I mimetic peptide containing
a proline residue has greater in vivo HDL binding and anti-inﬂammatory ability
than the 4F peptide, J. Lipid Res. (2009) M900151–MJLR200.
[40] B.J. Van Lenten, A.C. Wagner, M. Navab, G.M. Anantharamaiah, E.K. Hui, D.P. Nayak,
A.M. Fogelman, D-4F, an apolipoprotein A-I mimetic peptide, inhibits the
inﬂammatory response induced by inﬂuenza A infection of human type II
pneumocytes, Circulation 110 (2004) 3252–3258.
[41] M. Navab, G.M. Anantharamaiah, S.T. Reddy, B.J. Van Lenten, G. Datta, D. Garber,
A.M. Fogelman, Human apolipoprotein A-I and A-I mimetic peptides: potential for
atherosclerosis reversal, Curr. Opin. Lipidol. 15 (2004) 645–649.
[42] M. Navab, G.M. Anantharamaiah, S.T. Reddy, S. Hama, G. Hough, V.R. Grijalva, A.C.
Wagner, J.S. Frank, G. Datta, D. Garber, A.M. Fogelman, Oral D-4F causes formation
of pre-beta high-density lipoprotein and improves high-density lipoprotein-
mediated cholesterol efﬂux and reverse cholesterol transport from macrophages
in apolipoprotein E-null mice, Circulation 109 (2004) 3215–3220.
[43] M. Navab, G.M. Anantharamaiah, S.T. Reddy, B.J. Van Lenten, G. Hough, A. Wagner,
K. Nakamura, D.W. Garber, G. Datta, J.P. Segrest, S. Hama, A.M. Fogelman, Human
apolipoprotein AI mimetic peptides for the treatment of atherosclerosis, Curr.
Opin. Investig. Drugs 4 (2003) 1100–1104.
[44] M. Navab, G.M. Anantharamaiah, S. Hama, D.W. Garber, M. Chaddha, G. Hough, R.
Lallone, A.M. Fogelman, Oral administration of an Apo A-I mimetic peptide
synthesized from D-amino acids dramatically reduces atherosclerosis in mice
independent of plasma cholesterol, Circulation 105 (2002) 290–292.
[45] D.W. Garber, G. Datta, M. Chaddha, M.N. Palgunachari, S.Y. Hama, M. Navab, A.M.
Fogelman, J.P. Segrest, G.M. Anantharamaiah, A new synthetic class A amphipathic
peptide analogue protects mice from diet-induced atherosclerosis, J. Lipid Res. 42
(2001) 545–552.
[46] M. Navab, G.M. Anantharamaiah, S.T. Reddy, S. Hama, G. Hough, V.R. Grijalva, N.
Yu, B.J. Ansell, G. Datta, D.W. Garber, A.M. Fogelman, Apolipoprotein A-I mimetic
peptides, Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1325–1331.[47] G.S. Getz, G.D. Wool, C.A. Reardon, Apoprotein A-I mimetic peptides and their
potential anti-atherogenic mechanisms of action, Curr. Opin. Lipidol. 20 (2009)
171–175.
[48] M. Navab, G.M. Anantharamaiah, A.M. Fogelman, The effect of apolipoprotein
mimetic peptides in inﬂammatory disorders other than atherosclerosis, Trends
Cardiovasc. Med. 18 (2008) 61–66.
[49] B.J. Van Lenten, M. Navab, G.M. Anantharamaiah, G.M. Buga, S.T. Reddy, A.M.
Fogelman, Multiple indications for anti-inﬂammatory apolipoprotein mimetic
peptides, Curr. Opin. Investig. Drugs 9 (2008) 1157–1162.
[50] H.P. Deigner, A. Hermetter, Oxidized phospholipids: emerging lipid mediators in
pathophysiology, Curr. Opin. Lipidol. 19 (2008) 289–294.
[51] N.D. Vaziri, H. Moradi, M.V. Pahl, A.M. Fogelman, M. Navab, In vitro stimulation of
HDL anti-inﬂammatory activity and inhibition of LDL pro-inﬂammatory activity in
the plasma of patients with end-stage renal disease by an apoA-1 mimetic
peptide, Kidney Int. (in press), doi:10.1038/ki.2009.177.
[52] H. Gupta, L. Dai, G. Datta, D.W. Garber, H. Grenett, Y. Li, V. Mishra, M.N.
Palgunachari, S. Handattu, S.H. Gianturco, W.A. Bradley, G.M. Anantharamaiah,
C.R. White, Inhibition of lipopolysaccharide-induced inﬂammatory responses by
an apolipoprotein AI mimetic peptide, Circ. Res. 97 (2005) 236–243.
[53] M. Navab, G.M. Anantharamaiah, S. Hama, G. Hough, S.T. Reddy, J.S. Frank, D.W.
Garber, S. Handattu, A.M. Fogelman, D-4F and statins synergize to render HDL
antiinﬂammatory in mice and monkeys and cause lesion regression in old
apolipoprotein E-null mice, Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1426–1432.
[54] A.L. Kruger, S. Peterson, S. Turkseven, P.M. Kaminski, F.F. Zhang, S. Quan, M.S.
Wolin, N.G. Abraham, D-4F induces heme oxygenase-1 and extracellular super-
oxide dismutase, decreases endothelial cell sloughing, and improves vascular
reactivity in rat model of diabetes, Circulation 111 (2005) 3126–3134.
[55] S.J. Peterson, D. Husney, A.L. Kruger, R. Olszanecki, F. Ricci, L.F. Rodella, A.
Stacchiotti, R. Rezzani, J.A. McClung, W.S. Aronow, S. Ikehara, N.G. Abraham, Long-
term treatment with the apolipoprotein A1 mimetic peptide increases antiox-
idants and vascular repair in type I diabetic rats, J. Pharmacol. Exp. Ther. 322 (2007)
514–520.
[56] B.J. Van Lenten, A.C. Wagner, C.L. Jung, P. Ruchala, A.J. Waring, R.I. Lehrer, A.D.
Watson, S. Hama, M. Navab, G.M. Anantharamaiah, A.M. Fogelman, Anti-
inﬂammatory apoA-I-mimetic peptides bind oxidized lipids with much higher
afﬁnity than human apoA-I, J. Lipid Res. 49 (2008) 2302–2311.
[57] R.M. Epand, R.F. Epand, B.G. Sayer, G. Datta,M. Chaddha, G.M. Anantharamaiah, Two
homologous apolipoprotein AImimetic peptides. Relationship betweenmembrane
interactions and biological activity, J. Biol. Chem. 279 (2004) 51404–51414.
[58] V.K. Mishra, M.N. Palgunachari, R. Krishna, J. Glushka, J.P. Segrest, G.M.
Anantharamaiah, Effect of leucine to phenylalanine substitution on the nonpolar
face of a class A amphipathic helical peptide on its interaction with lipid: high
resolution solution NMR studies of 4F-dimyristoylphosphatidylcholine discoidal
complex, J. Biol. Chem. 283 (2008) 34393–34402.
[59] M. Navab, S.Y. Hama, G.M. Anantharamaiah, K. Hassan, G.P. Hough, A.D. Watson,
S.T. Reddy, A. Sevanian, G.C. Fonarow, A.M. Fogelman, Normal high density
lipoprotein inhibits three steps in the formation of mildly oxidized low density
lipoprotein: steps 2 and 3, J Lipid Res. 41 (2000) 1495–1508.
[60] M. Navab, S.Y. Hama, C.J. Cooke, G.M. Anantharamaiah, M. Chaddha, L. Jin, G.
Subbanagounder, K.F. Faull, S.T. Reddy, N.E. Miller, A.M. Fogelman, Normal high
density lipoprotein inhibits three steps in the formation of mildly oxidized low
density lipoprotein: step 1, J. Lipid Res. 41 (2000) 1481–1494.
[61] G. Datta, M. Chaddha, S. Hama, M. Navab, A.M. Fogelman, D.W. Garber, V.K. Mishra,
R.M. Epand, R.F. Epand, S. Lund-Katz,M.C. Phillips, J.P. Segrest, G.M. Anantharamaiah,
Effects of increasing hydrophobicity on the physical–chemical and biological
properties of a class A amphipathic helical peptide, J. LipidRes. 42 (2001)1096–1104.
[62] G. Privalov, V. Kavina, E. Freire, P.L. Privalov, Precise scanning calorimeter for
studying thermal properties of biological macromolecules in dilute solution, Anal.
Biochem. 232 (1995) 79–85.
[63] B.N. Ames, Assay of inorganic phosphate, total phosphate and phosphatases.
Methods Enzymol. 8 (1966) 115–118.
[64] G. Datta, R.F. Epand, R.M. Epand, M. Chaddha, M.A. Kirksey, D.W. Garber, S. Lund-
Katz, M.C. Phillips, S. Hama, M. Navab, A.M. Fogelman, M.N. Palgunachari, J.P.
Segrest, G.M. Anantharamaiah, Aromatic residue position on the nonpolar face of
class A amphipathic helical peptides determines biological activity, J. Biol. Chem.
279 (2004) 26509–26517.
[65] Y.V. Venkatachalapathi, M.C. Phillips, R.M. Epand, R.F. Epand, E.M. Tytler, J.P.
Segrest, G.M. Anantharamaiah, Effect of end group blockage on the properties of a
class A amphipathic helical peptide, Proteins 15 (1993) 349–359.
[66] G.M. Anantharamaiah, V.K. Mishra, D.W. Garber, G. Datta, S.P. Handattu, M.N.
Palgunachari, M. Chaddha, M. Navab, S.T. Reddy, J.P. Segrest, A.M. Fogelman,
Structural requirements for antioxidative and anti-inﬂammatory properties of
apolipoprotein A-I mimetic peptides, J. Lipid Res. 48 (2007) 1915–1923.
